Drugs / Marketed varicella vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT06806137 | May 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT06740630 Comparator | Jan 2025 → Dec 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT06693895 Comparator | Nov 2024 → Nov 2026 expected | chickenpox | GlaxoSmithKline | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Marketed varicella vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06740630 ↗ |
| Known as | Varivax | “an already approved varicella vaccine (VV) known as Varivax” NCT06740630 ↗2“an already approved varicella vaccine (VV) known as Varivax” NCT06693895 ↗ “already approved varicella vaccine, Varivax (VV)” NCT06806137 ↗ |
| Modality | Vaccine | “approved varicella vaccine (VV)” NCT06693895 ↗ |
| Route | Subcutaneous | “administered subcutaneously” NCT06693895 ↗ |